ASCO 2023 | Response-stratified chemoradiation enhances deep response rates in HNSCC

Ari Rosenberg, MD, University of Chicago, Chicago, IL, discusses findings from the Phase II DEPEND trial (NCT03944915), which assessed neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in patients with advanced HPV-negative head and neck squamous cell carcinoma (HNSCC). Nivolumab-based neoadjuvant chemoimmunotherapy resulted in deep responses, and response-adapted CRT led to promising survival. PD-1 status was additionally associated with deep responses. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.